Mar 6 |
Why BiomX Stock Is Surging Today
|
Mar 6 |
BiomX surges on merger deal with Adaptive Phage
|
Mar 6 |
BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing
|
Jan 4 |
BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis
|
Dec 7 |
BiomX files for $150M mixed shelf
|
Nov 30 |
BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023
|
Nov 29 |
Why Patterson Companies Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
|
Nov 29 |
BiomX mulls pivotal trial for antibacterial after Phase 1/2 data in cystic fibrosis
|
Nov 29 |
BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis
|
Nov 23 |
BiomX: BX004 Phage Cocktail Part 2, Phase 1b/2a Clinical Results In Cystic Fibrosis Expected Any Day
|